Last reviewed · How we verify
Disintegrating placebo tamsulosin tablet
Disintegrating placebo tamsulosin tablet is a Alpha-1A adrenergic receptor antagonist Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Benign prostatic hyperplasia with lower urinary tract symptoms.
Tamsulosin is an alpha-1A adrenergic receptor antagonist that relaxes smooth muscle in the prostate and bladder neck to improve urinary flow.
Tamsulosin is an alpha-1A adrenergic receptor antagonist that relaxes smooth muscle in the prostate and bladder neck to improve urinary flow. Used for Benign prostatic hyperplasia with lower urinary tract symptoms.
At a glance
| Generic name | Disintegrating placebo tamsulosin tablet |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Alpha-1A adrenergic receptor antagonist |
| Target | Alpha-1A adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Urology |
| Phase | Phase 3 |
Mechanism of action
Tamsulosin selectively blocks alpha-1A adrenergic receptors located on smooth muscle cells in the prostate and bladder outlet. This receptor antagonism causes smooth muscle relaxation, reducing urethral resistance and improving urine flow rate. The disintegrating tablet formulation is designed for rapid dissolution and absorption to provide faster symptom relief.
Approved indications
- Benign prostatic hyperplasia with lower urinary tract symptoms
Common side effects
- Retrograde ejaculation
- Dizziness
- Headache
- Asthenia/fatigue
- Orthostatic hypotension
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Disintegrating placebo tamsulosin tablet CI brief — competitive landscape report
- Disintegrating placebo tamsulosin tablet updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Disintegrating placebo tamsulosin tablet
What is Disintegrating placebo tamsulosin tablet?
How does Disintegrating placebo tamsulosin tablet work?
What is Disintegrating placebo tamsulosin tablet used for?
Who makes Disintegrating placebo tamsulosin tablet?
What drug class is Disintegrating placebo tamsulosin tablet in?
What development phase is Disintegrating placebo tamsulosin tablet in?
What are the side effects of Disintegrating placebo tamsulosin tablet?
What does Disintegrating placebo tamsulosin tablet target?
Related
- Drug class: All Alpha-1A adrenergic receptor antagonist drugs
- Target: All drugs targeting Alpha-1A adrenergic receptor
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Urology
- Indication: Drugs for Benign prostatic hyperplasia with lower urinary tract symptoms
- Compare: Disintegrating placebo tamsulosin tablet vs similar drugs
- Pricing: Disintegrating placebo tamsulosin tablet cost, discount & access